31 |
Práce s číselnými a algebraickými výrazy na základní škole / Working with numerical and algebraic expression in the compulsory educationPantůčková, Lenka January 2017 (has links)
Title: Working with numerical and algebraic expressions in the compulsory education Author: Bc. Lenka Pantůčková Department: Department of Mathametics and Mathematical Education Supervisor: Prof. RNDr. Jarmila Novotná, CSc. This Diploma Thesis deals with numerical and algebraic expressions in elementary school. The theoretical part deals with the framework educational programme for elementary education and grammar schools. It further mentions the propaedeutic of algebraic expressions at the first and second levels. It also introduces the most frequent mistakes done in calculating algebraic expressions. Meanings for the variable are stated as well. The last pre-chapter of the theoretical part is focused on statistics, which is further used for the experiment result evaluation. The experimental part first states the aims and methods of the research. Selected elementary schools taking part in the experiment are further introduced. An analysis of mathematics text books for the eighth grade (mainly chapters concerning the algebraic expressions), the selected schools use in their lessons, is also carried out. The experimental part also introduces the test presented to 128 pupils. Further pre-chapters are devoted to hypotheses and expected mistakes in single subtasks. In the conclusion of the experimental...
|
32 |
Itinerário terapêutico de pacientes com artrite reumatoide em uso de medicamentos modificadores do curso da doença biológicos / Therapeutic itinerary of patients with rheumatoid arthritis using biologic disease-modifying antirheumatic drugsOliveira, Silvia Coimbra de 06 December 2017 (has links)
Introdução A artrite reumatoide (AR) é uma doença crônica autoimune degenerativa, de alta prevalência e alta morbimortalidade, com difícil diagnóstico em todo o mundo. O seu pronto diagnóstico e o rápido início com medicamentos modificadores do curso da doença (MMCD) impactam de forma relevante o prognóstico do paciente. Para alguns pacientes os MMCDs sintéticos não serão eficazes e este paciente deverá receber então um MMCD biológico, medicamento este de alto custo para o paciente e o sistema de saúde. Objetivo - Explorar as trajetórias percorridas na busca por cuidado por pacientes com AR em uso de MMCD biológico no município de São Paulo. Métodos - Pesquisa qualitativa, de caráter exploratório, com orientação analítico-descritiva, mediante entrevistas semiestruturadas com questões abertas, iniciada após prévia aprovação do Comitê de Ética em Pesquisa e consentimento esclarecido dos entrevistados. Os sujeitos são pacientes em uso de MMCD biológico para tratamento de AR dispensados pelo SUS. Foi utilizada a ferramenta do itinerário terapêutico (IT) para entendimento do caminho escolhido por estes pacientes na busca por cuidado em saúde. Resultados e Discussão Entre os entrevistados, a busca de cuidado ocorreu tardiamente, normalmente sem a suspeita de que se tratasse de doença reumática degenerativa. Os primeiros profissionais acessados foram o médico clínico geral ou o ortopedista, que raras vezes investigaram com atenção os sintomas relatados para em seguida proceder o encaminhamento adequado e rápido do paciente para o reumatologista. Nos ITs descritos, os tratamentos na sua maioria são constituídos apenas pelos medicamentos, e sem a participação de outros profissionais no acompanhamento além do reumatologista. Os pacientes entrevistados chegaram até o MMCD biológico após tentativa de controle da doença com os MMCDs sintéticos, conforme descreve o protocolo de tratamento do Ministério da Saúde. Há nos ITs descritos diversos atores representantes da iniciativa privada, que apoiam e influenciam estes pacientes na escolha dos seus caminhos por cuidado de saúde, que devem ser melhor compreendidos em estudos futuros / Introduction Rheumatoid arthritis (RA) is a chronic degenerative autoimmune disease of high prevalence and with high morbidity and mortality, worldwide difficult to diagnose. Its prompt diagnosis and rapid onset with disease modifying drugs (DMARD) have a relevant impact on the patient\'s prognosis. For some patients, the synthetic DMARDs will not be effective so these patients should receive a biological DMARD - a high cost medication both to the patient and the health system. Objective - To explore the trajectories performed by patients with RA using biological DMARD in the search for care in the city of São Paulo. Methods - Qualitative research, with an exploratory character, with analytical-descriptive orientation, through semi-structured interviews with open questions, initiated after prior approval of the Committee on Ethics in Research and informed consent of the interviewees. The subjects are patients using biological DMARD to treat RA that were dispensed by SUS. The therapeutic itinerary tool (TI) was used to understand the path chosen by these patients in the search for health care. Results and Discussion Among those interviewees, the search for care occurred late, usually without the suspicion that there was a degenerative rheumatic disease. The first accessed professionals were the general practitioner or the orthopedist, who rarely ever investigated the reported symptoms with attention to direct the patient to the rheumatologist quickly. In the described TIs, the treatments are mostly composed only by the medicines, and without the participation of other professionals in the follow-up besides the rheumatologist. The patients interviewed reached the biological DMARDs after an attempt to control the disease with synthetic DMARD, as described in the Ministry of Health recommendations. There are several actors representing the private sector described in the TI\'s, who support and influence the patients in the choice of their care pathways, which should be better understood in future studies
|
33 |
Itinerário terapêutico de pacientes com artrite reumatoide em uso de medicamentos modificadores do curso da doença biológicos / Therapeutic itinerary of patients with rheumatoid arthritis using biologic disease-modifying antirheumatic drugsSilvia Coimbra de Oliveira 06 December 2017 (has links)
Introdução A artrite reumatoide (AR) é uma doença crônica autoimune degenerativa, de alta prevalência e alta morbimortalidade, com difícil diagnóstico em todo o mundo. O seu pronto diagnóstico e o rápido início com medicamentos modificadores do curso da doença (MMCD) impactam de forma relevante o prognóstico do paciente. Para alguns pacientes os MMCDs sintéticos não serão eficazes e este paciente deverá receber então um MMCD biológico, medicamento este de alto custo para o paciente e o sistema de saúde. Objetivo - Explorar as trajetórias percorridas na busca por cuidado por pacientes com AR em uso de MMCD biológico no município de São Paulo. Métodos - Pesquisa qualitativa, de caráter exploratório, com orientação analítico-descritiva, mediante entrevistas semiestruturadas com questões abertas, iniciada após prévia aprovação do Comitê de Ética em Pesquisa e consentimento esclarecido dos entrevistados. Os sujeitos são pacientes em uso de MMCD biológico para tratamento de AR dispensados pelo SUS. Foi utilizada a ferramenta do itinerário terapêutico (IT) para entendimento do caminho escolhido por estes pacientes na busca por cuidado em saúde. Resultados e Discussão Entre os entrevistados, a busca de cuidado ocorreu tardiamente, normalmente sem a suspeita de que se tratasse de doença reumática degenerativa. Os primeiros profissionais acessados foram o médico clínico geral ou o ortopedista, que raras vezes investigaram com atenção os sintomas relatados para em seguida proceder o encaminhamento adequado e rápido do paciente para o reumatologista. Nos ITs descritos, os tratamentos na sua maioria são constituídos apenas pelos medicamentos, e sem a participação de outros profissionais no acompanhamento além do reumatologista. Os pacientes entrevistados chegaram até o MMCD biológico após tentativa de controle da doença com os MMCDs sintéticos, conforme descreve o protocolo de tratamento do Ministério da Saúde. Há nos ITs descritos diversos atores representantes da iniciativa privada, que apoiam e influenciam estes pacientes na escolha dos seus caminhos por cuidado de saúde, que devem ser melhor compreendidos em estudos futuros / Introduction Rheumatoid arthritis (RA) is a chronic degenerative autoimmune disease of high prevalence and with high morbidity and mortality, worldwide difficult to diagnose. Its prompt diagnosis and rapid onset with disease modifying drugs (DMARD) have a relevant impact on the patient\'s prognosis. For some patients, the synthetic DMARDs will not be effective so these patients should receive a biological DMARD - a high cost medication both to the patient and the health system. Objective - To explore the trajectories performed by patients with RA using biological DMARD in the search for care in the city of São Paulo. Methods - Qualitative research, with an exploratory character, with analytical-descriptive orientation, through semi-structured interviews with open questions, initiated after prior approval of the Committee on Ethics in Research and informed consent of the interviewees. The subjects are patients using biological DMARD to treat RA that were dispensed by SUS. The therapeutic itinerary tool (TI) was used to understand the path chosen by these patients in the search for health care. Results and Discussion Among those interviewees, the search for care occurred late, usually without the suspicion that there was a degenerative rheumatic disease. The first accessed professionals were the general practitioner or the orthopedist, who rarely ever investigated the reported symptoms with attention to direct the patient to the rheumatologist quickly. In the described TIs, the treatments are mostly composed only by the medicines, and without the participation of other professionals in the follow-up besides the rheumatologist. The patients interviewed reached the biological DMARDs after an attempt to control the disease with synthetic DMARD, as described in the Ministry of Health recommendations. There are several actors representing the private sector described in the TI\'s, who support and influence the patients in the choice of their care pathways, which should be better understood in future studies
|
34 |
Efeito radiomodificador do resveratrol em cultura de células de rabdomiossarcoma humano (RD) aplicando o teste do cometa / Radiomodifying effect of resveratrol in human rhabdomyosarcoma (RD) cell culture applying the comet assayMAGALHAES, VANESSA D. 09 October 2014 (has links)
Made available in DSpace on 2014-10-09T12:35:46Z (GMT). No. of bitstreams: 0 / Made available in DSpace on 2014-10-09T14:03:54Z (GMT). No. of bitstreams: 0 / Dissertação (Mestrado) / IPEN/D / Instituto de Pesquisas Energeticas e Nucleares - IPEN-CNEN/SP
|
35 |
Efeito radiomodificador do resveratrol em cultura de células de rabdomiossarcoma humano (RD) aplicando o teste do cometa / Radiomodifying effect of resveratrol in human rhabdomyosarcoma (RD) cell culture applying the comet assayMAGALHAES, VANESSA D. 09 October 2014 (has links)
Made available in DSpace on 2014-10-09T12:35:46Z (GMT). No. of bitstreams: 0 / Made available in DSpace on 2014-10-09T14:03:54Z (GMT). No. of bitstreams: 0 / O câncer é uma doença de alta incidência e é considerado um problema de saúde pública no mundo todo. O resveratrol é um polifenol de defesa que tem a habilidade de inibir a carcinogênese em múltiplos estágios. Este polifenol é sintetizado por uma grande variedade de plantas em resposta a exposição à radiação ultravioleta (UV) ou também, pelo estresse mecânico produzido pela ação de patógenos, agentes químicos e físicos. As videiras são consideradas as plantas que têm uma capacidade elevada de produzir o resveratrol, portanto suco de uva e vinho, principalmente o vinho tinto são considerados uma boa fonte de resveratrol. Os efeitos protetores exercidos pelo resveratrol promovem efeitos como indução da resposta antiinflamatória, atividade antitumoral, prevenção ou inibição de doenças degenerativas, diminuição da incidência de doenças cardiovasculares, inibição da agregação plaquetária, entre outros. Assim, o resveratrol é considerado um protetor celular. Porém, em concentrações mais elevadas, o resveratrol promove o efeito contrário, sensibilizando as células a algum tipo de efeito, como por exemplo, o efeito da radiação ionizante. O objetivo desse trabalho foi estudar o efeito radiomodificador do resveratrol em cultura de células RD (rabdomiossarcoma humano) aplicando o teste do cometa para avaliação do dano e capacidade de reparo celular. Foi obtida a DL50 das células RD em 403 Gy e o índice de citotoxicidade do resveratrol (IC50%) nas células RD foi de 150 μM. A partir destes resultados foram definidas as doses de radiação gama (50 Gy e 100 Gy) e as concentrações de resveratrol (15 μM 30 μM 60 μM) que foram analisadas no trabalho. Foram evidenciados os efeitos do resveratrol como protetor celular na concentração de 15 μM e seu efeito citotóxico em 60 μM. Com a interação da radiação gama, a concentração de 60 μM não mostrou efeito radiossensibilizador estatisticamente significante. / Dissertação (Mestrado) / IPEN/D / Instituto de Pesquisas Energeticas e Nucleares - IPEN-CNEN/SP
|
36 |
Statistical Information Included in Labeling for Disease-Modifying Anti-Rheumatic Drugs for Rheumatoid ArthritisHatch, Lashley, Malone, Daniel C. January 2012 (has links)
Class of 2012 Abstract / Specific Aims: To evaluate the presence of statistical information from clinical studies in official product labeling specific for disease-modifying anti-rheumatic drugs (DMARDs) used in the treatment of rheumatoid arthritis.
Methods: Data were abstracted from official product labeling DMARDs with FDA approval for treatment of rheumatoid arthritis. Each document was examined for the presence of statement regarding a priori type 1 error rate, p-values, and measures of variance. Medications were classified as either biologic or non-biologic.
Main Results: A total of 14 DMARDs, 7 biologics (50%) and 7 non-biologics (50%), were found to be FDA approved for the treatment of rheumatoid arthritis. Primary outcomes consisted of American College of Rheumatology (ACR) response rates, radiographic changes, and health assessment questionnaire score (HAQ). Any measure of variance and the presence of a p-value were both found in six (43%) of the drug labels. Inclusion of p-values was found to be significantly greater in biologics compared to non-biologics for both ACR and radiographic results. Inclusion of variance was found to be significantly greater in biologics compared to non-biologics for radiographic changes only. No package inserts contained statements regarding the a priori type I error rate.
Conclusions: Measures of variance are not frequently included in product labeling for either biologic or non-biologic DMARDs. However, inclusion of variance and p-values for ACR response rates and radiographic changes were more likely to be reported for biologics therapies as compared to non-biologics. A statement regarding Type 1 error rates were absent from labels regardless of outcome assessed.
|
37 |
Computational Methods for the structural and dynamical understanding of GPCR-RAMP interactionsBahena, Silvia January 2020 (has links)
Protein-protein interaction dominates all major biology processes in living cells. Recent studies suggestthat the surface expression and activity of G protein-coupled receptors (GPCRs), which are the largestfamily of receptors in human cells, can be modulated by receptor activity–modifying proteins (RAMPs). Computational tools are essential to complement experimental approaches for the understanding ofmolecular activity of living cells and molecular dynamics simulations are well suited to providemolecular details of proteins function and structure. The classical atom-level molecular modeling ofbiological systems is limited to small systems and short time scales. Therefore, its application iscomplicated for systems such as protein-protein interaction in cell-surface membrane. For this reason, coarse-grained (CG) models have become widely used and they represent an importantstep in the study of large biomolecular systems. CG models are computationally more effective becausethey simplify the complexity of the protein structure allowing simulations to have longer timescales. The aim of this degree project was to determine if the applications of coarse-grained molecularsimulations were suitable for the understanding of the dynamics and structural basis of the GPCRRAMP interactions in a membrane environment. Results indicate that the study of protein-proteininteractions using CG needs further improvement with a more accurate parameterization that will allowthe study of complex systems.
|
38 |
Medication Patterns and Comparative Effectiveness Research of Biologic Disease-modifying Antirheumatic Drugs in Children Newly Diagnosed with Juvenile Idiopathic Arthritis using Electronic Medical RecordsYue, Xiaomeng January 2020 (has links)
No description available.
|
39 |
Predictors of Adherence Among Patients With Multiple Sclerosis Using the BETACONNECT® Autoinjector: A Prospective Observational Cohort StudyKöhler, Wolfgang, Bayer-Gersmann, Kirsten, Neußer, Thomas, Schürks, Markus, Ziemssen, Tjalf 27 March 2023 (has links)
Background: In patients with multiple sclerosis (MS), non-adherence to
disease-modifying drug therapy is associated with an increased rate of MS relapses.
Early identification of patients at risk of non-adherence would allow provision of timely
and individualized support. The aim of the BETAPREDICT study was to investigate
potential predictors of adherence in patients with MS in Germany treated with interferon
β-1b (IFNβ-1b) using the BETACONNECT® autoinjector.
Methods: BETAPREDICT was a national, multi-center, prospective, non-interventional,
single-arm, 24-month cohort study of patients with relapsing–remitting MS or
clinically isolated syndrome receiving IFNβ-1b via the BETACONNECT® autoinjector
(ClinicalTrials.gov: NCT02486640). Injection data were captured by the autoinjector. The
primary objective was to determine baseline predictors of compliance, persistence, and
adherence to IFNβ-1b treatment after 12- and 24 months using multivariable-adjusted
regression. Secondary objectives included evaluation of satisfaction with the autoinjector,
injection site pain, vitamin and nutrient supplementation, clinical course, and
patient-related outcome measures.
Results: Of 165 patients enrolled, 153 were available for analysis (120 with autoinjector
data). Seventy-two patients left the study prematurely. Compliance (N = 120),
persistence (N = 153), and adherence (N = 120) at 24 months were 89.1, 53.6,
and 41.7%, respectively. Compliance at 12- and 24 months was predicted by intake
of vitamin D supplements and absence of specific injection site reactions. Positive
predictors of persistence included age (at 12- and 24 months) and previous duration
of treatment (at 12 months), while intake of vitamins/nutrients other than vitamin D was
a negative predictor (at 12 months). Positive predictors of adherence at 24 months were
age and being experienced with IFNβ-1b. Higher scores in specific SF-36 subscales
were positive predictors of medication-taking behavior at 24 months. Satisfaction with
the autoinjector was high at baseline and 24 months (median score: 9 out of 10).
Conclusions: Compliance with IFNβ-1b treatment among participants still under
observation remained high over a 24-month period, while persistence and adherence
continuously declined. Multiple factors affected medication-taking behavior, including
patient characteristics, treatment history, injection site reactions, patients’ perception of
their health and support programs. The importance of these factors may differ among
patients according to their individual situation.
|
40 |
Public Health Aspects of Pharmaceutical Prescription Patterns : Exemplified by treatments for prevention of cardiovascular diseaseSilwer, Louise January 2007 (has links)
Public health aspects of pharmaceutical prescription patterns: Exemplified by treatments for prevention of cardiovascular disease. Louise Silwer. ISBN: 978-91-85721-18-4 ISSN: 0283-1961Main aim:To study patterns and trends of dispensed prescriptions, to explore what proportion of the population is exposed to some of the more prevalently prescribed pharmaceuticals, and to find possible ways of measuring drug-induced adverse symptoms in the population. Further, to illuminate conditions surrounding prescribing in primary prevention of cardiovascular disease. Methods: In three descriptive studies of prescription patterns, prescription data at aggregate level from a Swedish county were analysed retrospectively, and proportions were calculated. Data from the first ten years of the studies were obtained from a local prescription study, and data from another five years were local data from a national prescription survey. Data from a Danish database (OPED), with data at the individual level, were used for a prescription sequence symmetry analysis, and when Swedish national prescription data at the individual level became accessible, they were used for calculations of drug prevalence in the entire Swedish population. In a qualitative analysis of interview data, a phenomenographic approach was used. Main results: The purchase of pharmaceuticals on prescription almost doubled in the studied county in the period 1988-2002. Some common pharmaceuticals that increased to a great extent among the older part of the population were cardiovascular preventive drugs, such as antihypertensive and lipid modifying agents, and also hormone replacement therapy for women. In 2005, over half of all Swedish citizens, aged 60 or over, purchased antihypertensive or lipid modifying preparations during a six-month period. The different views that were found among GPs, regarding beliefs and practical management of primary prevention of CVD, could be interpreted as a reflection of the complexity of patient counselling in primary prevention in practice. Conclusion: The increase in dispensed prescriptions over the 15 years and the magnitude of the prevalence of the studied pharmaceuticals, such as antihypertensive, lipid modifying and hormonal treatments, which to a great extent are used by ‘healthy’ people, point to the need of following-up both beneficial and harmful consequences on public health. The prevalence of preventive treatments together with the variation in views of administration of primary prevention of cardiovascular disease, also point to the need of clarification of guidelines regarding pharmaceutical primary prevention and encouragement of therapy discussions among GPs.
|
Page generated in 0.0694 seconds